ArticleFuture oncology (London, England)2025

PERI-START: a phase II trial of perioperative TACE, tislelizumab, and lenvatinib in early-stage hepatocellular carcinoma.

Diao Kong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.